kabutan

BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Narrows

Fri Feb 14, 2025 3:30 pm JST Earnings

4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】

Earnings Report

BrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced its financial results after the market closed on February 14th (15:30). The net loss (non-consolidated) for the cumulative third quarter of the fiscal year ending March 2025 (April to December) was a reduced loss of 815 million yen (compared to a loss of 953 million yen in the same period last year).

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the net loss for the January to March period (4Q) is expected to further decrease loss of 112 million yen (compared to a loss of 215 million yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the net loss improved to a deficit of 277 million yen (compared to a loss of 400 million yen in the same period last year).

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 5 -1,218 -1,223 -1,225 -20.9 ー Feb 10, 2023 J-GAAP
Apr - Dec, 2023 0 -947 -947 -953 -15.1 ー Feb 9, 2024 J-GAAP
Apr - Dec, 2024 0 -815 -812 -815 -10.3 ー Feb 14, 2025 J-GAAP
YoY － +13.9% +14.3% +14.5% +32.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 0 -605 -607 -615 -9.6 0 May 10, 2024 J-GAAP
Oct - Mar, 2024 Guidance 0 -383 -388 -389 -4.4 0 Nov 8, 2024 J-GAAP
YoY － +36.7% +36.1% +36.7% +54.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 5 -1,467 -1,473 -1,485 -24.9 0 May 12, 2023 J-GAAP
Mar, 2024 0 -1,155 -1,158 -1,168 -18.2 0 May 10, 2024 J-GAAP
Mar, 2025 Guidance 0 -925 -925 -927 -10.4 0 May 10, 2024 J-GAAP
YoY － +19.9% +20.1% +20.6% +43.1%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 0 -397 -396 -400 -6.4 -Inf Feb 9, 2024 J-GAAP
Jan - Mar, 2024 0 -208 -211 -215 -3.4 -Inf May 10, 2024 J-GAAP
Apr - Jun, 2024 0 -326 -329 -330 -4.7 -Inf Aug 9, 2024 J-GAAP
Jul - Sep, 2024 0 -216 -208 -208 -2.8 -Inf Nov 8, 2024 J-GAAP
Oct - Dec, 2024 0 -273 -275 -277 -3.5 -Inf Feb 14, 2025 J-GAAP
YoY － +31.2% +30.6% +30.8% +44.9%

Related Articles